| Methods |
Multicentre, double‐blind, placebo‐controlled
Randomisation technique not stated
ITT analysis |
| Participants |
USA, 19 participants
Age: > 45 years
No genders given
Inclusion: IS diagnosed on history and neurological examination
Enrolment times not given |
| Interventions |
T: nimodipine (Miles Pharmaceuticals, USA) 120 mg/day po in 6 divided doses
C: matching placebo
Rx: for 21 days |
| Outcomes |
Brachial BP before and 30 and 60 minutes after each morning dose for 7 days
BP methodology not stated
DBP estimated from SBP and MAP given in paper |
| Notes |
Ex: concurrent calcium channel antagonists, antihypertensive agents (other than beta blockers)
Admission times of concurrent medication always separated from study drug administration by at least 2 hours
Part of a larger unpublished trial to evaluate the safety and efficacy of nimodipine |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Adequate sequence generation? |
Low risk |
Probably done |
| Allocation concealment? |
Unclear risk |
Unclear from the publication |
| Blinding? |
Low risk |
Probably done |
| Completeness of follow‐up |
Unclear risk |
Unclear from the publication |
